30 days! China Resources Pharmaceutical Co., Ltd. took over 4.2 billion cash of Jiangzhong Pharmaceutical Co., Ltd. and collected 1 billion varieties

Wonderful content on March 15, Jiangzhong Pharmaceutical Co., Ltd issued the first suggestive announcement on China Resources pharmaceutical's offer to acquire Jiangzhong Pharmaceutical Co., Ltd the price of this offer is 17.56 yuan / share, the number of offers is 239 million shares, the maximum total amount of funds is close to 4.202 billion yuan, and the payment method is cash payment On the same day, Jiangzhong pharmaceutical released its 2018 annual report, with annual revenue of 1.755 billion yuan, a year-on-year increase of 0.49%; net profit of 470 million yuan, a year-on-year increase of 12.55%, of which the sales volume of core product Jianwei Xiaoshi tablets exceeded 1 billion yuan 4.2 billion cash! CR pharmaceutical's comprehensive tender offer launch relationship Recently, Jiangzhong Pharmaceutical Co., Ltd issued the first suggestive announcement on China Resources pharmaceutical's acquisition of Jiangzhong Pharmaceutical by offer According to the data, the validity period of this acquisition by offer is March 4-april 2, 2019, the price of acquisition by offer is 17.56 yuan / share, the number of acquisition by offer is 239 million shares, and the maximum total capital is 4.2 billion yuan The payment method is cash payment The required capital will come from the own capital of China Resources pharmaceutical in the future The decision-making, approval procedures and important information disclosure of listed companies involved in the capital increase and tender offer acquisition China Resources Pharmaceutical Co., Ltd became the controlling shareholder holding 51% of the equity of Jiangzhong group after the capital increase of Jiangzhong group Jiangzhong group is the controlling shareholder of the listed company Jiangzhong pharmaceutical, holding 43.03% of the issued shares of the listed company After the completion of this transaction, China Resources pharmaceutical indirectly owns more than 30% of the issued shares of Jiangzhong pharmaceutical through Jiangzhong group, thus triggering the obligation of comprehensive tender offer The purpose of this acquisition is to build CR Pharma into a leading comprehensive pharmaceutical and health group in China with Jiangzhong group as the development platform, and to drive the innovation and upgrading of Jiangxi pharmaceutical industry The recent performance of Jiangzhong Pharmaceutical Co., Ltd (unit: RMB 100 million) with 1 billion varieties of "eye-catching" According to the 2018 annual report, the revenue of Jiangzhong Pharmaceutical Co., Ltd is RMB 1.755 billion, an increase of 0.49% year on year; the net profit is RMB 470 million, an increase of 12.55% year on year The main business of Jiangzhong pharmaceutical industry includes over-the-counter medicine, health products and functional food The main products include Jiangzhong brand Jianwei Xiaoshi tablet, Jiangzhong brand Lactobacillin tablet, Jiangzhong brand compound Caoshanhu buccal tablet, shenlingcao oral liquid, Chuyuan oral liquid, etc The over-the-counter medicine business is an important part of the revenue of Jiangzhong pharmaceutical industry In 2018, the revenue reached 1.497 billion yuan, a year-on-year increase of 2.74%, accounting for 85% of the total revenue Jiangzhong pharmaceutical said that the over-the-counter drug sales terminals are mainly drugstores, and the sales terminals of health products are mainly large-scale shopping malls, supermarkets and stores The sales are mainly carried out by distributors, large-scale chain strategic cooperation and large-scale supermarket direct sales The company is mainly responsible for the advertising and publicity investment of products, and participates in terminal expansion, promotion and customer maintenance It is understood that the company has established a channel fine control system covering 21 provinces, 5 autonomous regions and 4 municipalities directly under the central government, excluding Tibet and Taiwan In addition, we also actively explore and develop e-commerce sales as a supplement to the existing sales system It is worth mentioning that Jianwei Xiaoshi tablet is the core product of Jiangzhong pharmaceutical, with an annual sales of more than 1 billion yuan According to the data of minenet, among the top 20 brands of Jianwei Xiaoshi tablet in China's urban retail drugstores, Jiangzhong pharmaceutical occupies more than 90% of the market share In 2017, the top 20 brand pattern of terminal Jianwei Xiaoshi tablet in China's urban retail drugstores promoted the extension and layout of the future, expanded the advantage resources of traditional Chinese medicine from January to February 2019 Jiangzhong pharmaceutical successively completed the industrial and commercial change procedures related to the acquisition of 51% equity of Sanghai pharmaceutical and Jisheng pharmaceutical, the reorganization of China Resources Jiangzhong group and the change of actual controller, and the handover work is being carried out in an orderly manner According to the data, Sanghai pharmaceutical and Jisheng pharmaceutical have more than 200 product approvals, covering respiratory system, digestive system, urinary system, cardio cerebrovascular and other fields, including Chuanbei loquat capsule, compound fresh bamboo juice, Bazhen Yimu capsule, Niuhuang snake bile Chuanbei liquid and other famous products, among which Chuanbei loquat capsule, Bazhen Yimu capsule and Shenbao capsule are exclusive varieties Jiangzhong pharmaceutical said that in terms of business structure, it has changed from relying solely on Jiangzhong brand Jianwei Xiaoshi tablets, Caoshanhu buccal tablets, Lactobacillin tablets and other products in the past to a business layout based on the existing OTC and health care products business, and combining the OTC business of traditional Chinese medicine of Sanghai pharmaceutical and Jisheng pharmaceutical with the traditional Chinese medicine business of traditional Chinese medicine division; At the same time, the number of product approvals has increased from dozens to more than 200, covering areas ranging from gastrointestinal digestion assistance, upper respiratory tract extension or expansion to urinary system, digestive system, cardio cerebrovascular, tranquilizing mind and tonifying brain In the future, on the one hand, we will actively sort out and plan the products and businesses of Sanghai pharmaceutical and Jisheng pharmaceutical to promote resource complementarity and business collaboration; on the other hand, we will actively integrate into the China Resources System in accordance with the regulatory requirements of listed companies and the management regulations of central enterprises At the same time, under the management system of China Resources pharmaceutical, further improve and sort out the development strategy to lay out the business transformation and development.